GlassScriptPhysician profile
Amy B White
NPI 1235831553
$4,209.71
in general payments reported to CMS, 2019-2025
26 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $687 · 2024: $2,325 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $566.08 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $508.97 | 2023-2025 | |
| Lilly USA, LLC | $490.01 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $458.06 | 2023-2025 | |
| Novo Nordisk INC | $426.00 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $357.27 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.33 | 2023-2025 | Caplyta |
| Amgen INC. | $148.37 | 2023-2024 | Otezla, Repatha, Prolia |
| Xeris Pharmaceuticals, INC. | $132.35 | 2024-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Shield Therapeutics INC | $131.03 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $120.59 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $120.13 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.48 | 2023-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $54.49 | 2023 | Korlym |
| Merck Sharp & Dohme LLC | $48.77 | 2023 | Verquvo, Belsomra, Steglatro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $37.61 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Otsuka America Pharmaceutical, INC. | $36.31 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.57 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $34.28 | 2024 | Xarelto |
| Sumitomo Pharma America, INC. | $33.52 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $31.01 | 2024-2025 | Nexletol |
| Axsome Therapeutics, INC. | $27.39 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $26.31 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $23.99 | 2023 | |
| Inspire Medical Systems, INC. | $18.60 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $15.19 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.